发布求助
文献互助 智能选刊 最新文献

Future Prescriber最新文献

筛选
英文 中文
Etanercept: a new option in paediatric plaque psoriasis 依那西普:治疗小儿斑块型银屑病的新选择
Future Prescriber Pub Date : 2009-01-19 DOI: 10.1002/fps.36
Steve Chaplin MSc, MRPharmS, Dr David Atherton MA, MB, BChir, FRCP
{"title":"Etanercept: a new option in paediatric plaque psoriasis","authors":"Steve Chaplin MSc, MRPharmS,&nbsp;Dr David Atherton MA, MB, BChir, FRCP","doi":"10.1002/fps.36","DOIUrl":"10.1002/fps.36","url":null,"abstract":"<p>Psoriasis in children and adolescents can be disfiguring and adversely affect quality of life. A range of treatments are available that can control the condition, but not all patients respond or are able to tolerate the treatments. The anti-TNF alpha inhibitors are used effectively in adult psoriasis but are not currently licensed for use in children. The anti-TNF etanercept (Enbrel) has been studied in childhood psoriasis and is likely to gain a licence in the near future. In this article, the authors discuss current treatment approaches in childhood psoriasis and describe the efficacy, tolerability and potential place of etanercept in practice. Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"6-10"},"PeriodicalIF":0.0,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85064542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of type 2 diabetes: the GLP-1 pathway 2型糖尿病的治疗:GLP-1通路
Future Prescriber Pub Date : 2009-01-19 DOI: 10.1002/fps.39
Abd A Tahrani MMedSci, MD, MRCP, Milan K Piya MRCP, Anthony H Barnett MD, FRCP
{"title":"Management of type 2 diabetes: the GLP-1 pathway","authors":"Abd A Tahrani MMedSci, MD, MRCP,&nbsp;Milan K Piya MRCP,&nbsp;Anthony H Barnett MD, FRCP","doi":"10.1002/fps.39","DOIUrl":"https://doi.org/10.1002/fps.39","url":null,"abstract":"<p>Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1–5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy. Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137701132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Servier: establishing research and education partnerships 施维雅:建立研究和教育合作伙伴关系
Future Prescriber Pub Date : 2009-01-19 DOI: 10.1002/fps.38
{"title":"Servier: establishing research and education partnerships","authors":"","doi":"10.1002/fps.38","DOIUrl":"https://doi.org/10.1002/fps.38","url":null,"abstract":"<p>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Servier Laboratories and its top products, as well as Servier's ongoing development of research and education partnerships. Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.38","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137701131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rituximab therapy for chronic lymphocytic leukaemia 利妥昔单抗治疗慢性淋巴细胞白血病
Future Prescriber Pub Date : 2009-01-19 DOI: 10.1002/fps.37
Steve Chaplin MSc, MRPharmS
{"title":"Rituximab therapy for chronic lymphocytic leukaemia","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.37","DOIUrl":"10.1002/fps.37","url":null,"abstract":"<p>Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first-line treatment option for CLL in combination with fludarabine and cyclophos-phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"11-15"},"PeriodicalIF":0.0,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.37","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84686016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rivaroxaban: a new orally active direct inhibitor of Factor Xa 利伐沙班:一种新的口服活性Xa因子直接抑制剂
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.8
Steve Chaplin
{"title":"Rivaroxaban: a new orally active direct inhibitor of Factor Xa","authors":"Steve Chaplin","doi":"10.1002/fps.8","DOIUrl":"10.1002/fps.8","url":null,"abstract":"<p>Deep vein thrombosis (DVT) is a common complication in hospital patients who do not receive thromboprophylaxis. Due to the shortcomings of the available evidence the true incidence is unclear, but data from the placebo arms of randomised trials of thromboprophylaxis, believed to be the best source,<sup>1</sup> show that the incidence varies by specialty (Table 1). The risk in medical inpatients is often underestimated: the incidence of DVT is particularly high among patients admitted with stroke, heart failure or myocardial infarction.<sup>2</sup> However, patients undergoing orthopaedic surgery are at greatest risk, with DVT occurring in approximately one-quarter to one-half. There is also evidence to suggest that individual risk is influenced by a large number of risk factors (Table 2).<sup>1</sup> Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 1","pages":"11-19"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74810267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Fentanyl buccal tablet for cancer breakthrough pain 芬太尼口腔片剂治疗癌症突破疼痛
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.6
Giovambattista Zeppetella FRCP
{"title":"Fentanyl buccal tablet for cancer breakthrough pain","authors":"Giovambattista Zeppetella FRCP","doi":"10.1002/fps.6","DOIUrl":"10.1002/fps.6","url":null,"abstract":"<p>Pain is one of the most common symptoms of advanced cancer and has significant adverse effects on patients' functioning and quality of life.<sup>1</sup> A number of studies have established that pain can be controlled in the majority of patients using the World Health Organization (WHO) guidelines,<sup>2</sup> however, even when background pain is well controlled, 70–90 per cent of patients with advanced cancer also experience brief episodes or flares of severe pain, known as breakthrough pain.<sup>3</sup> Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 1","pages":"5-9"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77597301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Anti-TNF drugs in psoriasis and IBD - Where are we going? 抗肿瘤坏死因子药物治疗银屑病和IBD -我们将走向何方?
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.20
Richard Warren BSc (Hons) MBChB (Hons) MRCP, Christopher EM Griffiths FRCP FRCPath, James Lindsay PhD MRCP
{"title":"Anti-TNF drugs in psoriasis and IBD - Where are we going?","authors":"Richard Warren BSc (Hons) MBChB (Hons) MRCP,&nbsp;Christopher EM Griffiths FRCP FRCPath,&nbsp;James Lindsay PhD MRCP","doi":"10.1002/fps.20","DOIUrl":"10.1002/fps.20","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"14-20"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81125939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of unlicensed drugs: what are the issues? 使用未经许可的药物:问题是什么?
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.18
Peter Burrill
{"title":"Use of unlicensed drugs: what are the issues?","authors":"Peter Burrill","doi":"10.1002/fps.18","DOIUrl":"10.1002/fps.18","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88895137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An overview of the clinical trial data presented at the 44th American Society of Clinical Oncology Annual Meeting (ASCO) and the 9th Annual European Congress of Rheumatology (EULAR) 第44届美国临床肿瘤学会年会(ASCO)和第9届欧洲风湿病大会(EULAR)上提交的临床试验数据概述
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.17
Rhonda Siddall
{"title":"An overview of the clinical trial data presented at the 44th American Society of Clinical Oncology Annual Meeting (ASCO) and the 9th Annual European Congress of Rheumatology (EULAR)","authors":"Rhonda Siddall","doi":"10.1002/fps.17","DOIUrl":"10.1002/fps.17","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 2","pages":"22-23"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82700744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data presented at the 49th Annual Meeting of the American Society of Hematology held in Atlanta, Georgia in December 2007, has demonstrated dramatic positive results for the treatment of advanced follicular lymphoma with a single infusion of a combined anti-CD20 monoclonal antibody and a radioisotope. 2007年12月在乔治亚州亚特兰大举行的第49届美国血液学会年会上公布的数据显示，单次输注联合抗cd20单克隆抗体和放射性同位素治疗晚期滤泡性淋巴瘤有显著的积极效果。
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.7
Rhonda Siddall
{"title":"Data presented at the 49th Annual Meeting of the American Society of Hematology held in Atlanta, Georgia in December 2007, has demonstrated dramatic positive results for the treatment of advanced follicular lymphoma with a single infusion of a combined anti-CD20 monoclonal antibody and a radioisotope.","authors":"Rhonda Siddall","doi":"10.1002/fps.7","DOIUrl":"https://doi.org/10.1002/fps.7","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137801714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信